Tabor Asset Management LP Purchases Shares of 23,334 Bausch + Lomb Corporation (NYSE:BLCO)

Tabor Asset Management LP bought a new position in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 23,334 shares of the company's stock, valued at approximately $338,000.

Several other institutional investors have also added to or reduced their stakes in BLCO. Price T Rowe Associates Inc. MD bought a new stake in Bausch + Lomb in the 4th quarter valued at $14,122,000. Arrowstreet Capital Limited Partnership lifted its position in Bausch + Lomb by 51.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after acquiring an additional 414,138 shares in the last quarter. King Street Capital Management L.P. lifted its position in Bausch + Lomb by 55.2% in the 4th quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock valued at $20,522,000 after acquiring an additional 404,256 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in Bausch + Lomb in the 1st quarter valued at $4,712,000. Finally, Brevan Howard Capital Management LP bought a new stake in Bausch + Lomb in the 4th quarter valued at $5,385,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Stock Performance

NYSE BLCO traded down $0.14 on Thursday, hitting $14.10. 669,907 shares of the stock were exchanged, compared to its average volume of 760,245. The company has a market capitalization of $4.99 billion, a PE ratio of -13.69, a P/E/G ratio of 1.61 and a beta of 0.62. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.56 and a quick ratio of 0.96. The business's fifty day moving average is $12.54 and its 200 day moving average is $14.09. Bausch + Lomb Corporation has a 52 week low of $10.45 and a 52 week high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. Bausch + Lomb had a positive return on equity of 2.62% and a negative net margin of 7.50%. The firm's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 earnings per share. Research analysts anticipate that Bausch + Lomb Corporation will post 0.74 EPS for the current fiscal year.

Insider Buying and Selling

In other Bausch + Lomb news, CEO Brent L. Saunders acquired 22,000 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were purchased at an average price of $11.28 per share, for a total transaction of $248,160.00. Following the completion of the purchase, the chief executive officer directly owned 719,156 shares of the company's stock, valued at approximately $8,112,079.68. This represents a 3.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.76% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on BLCO. Citigroup boosted their price objective on shares of Bausch + Lomb from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Evercore ISI lifted their price objective on shares of Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Morgan Stanley reduced their target price on shares of Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Finally, Wells Fargo & Company lowered their price target on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $15.45.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.